Diagnostic and Prognostic Accuracy of Gold Nanoparticles in Salivary Gland Tumours
NCT ID: NCT04907422
Last Updated: 2021-09-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2018-08-06
2021-02-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Senstivity and Specificity of Using Salivary miRNAs in Detection of Malignant Transformation of Oral Lesions.
NCT04913545
Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
NCT05730855
The Effect of Sodium Fluoride Application on the Prevention of Radiation Caries in NPC Patients
NCT06174012
Diagnostic Accuracy of Fine Needle Aspiration in Patients With Salivary Gland Tumors.
NCT06034782
Efficacy of N-acetylcysteine in Preventing Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients.
NCT06354712
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CXPA group
carcinoma ex pleomorphic adenoma of major and minor salivary glands.
CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction
new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction
conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
PA group
Benign pleomorphic adenoma of major and minor salivary glands.
CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction
new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction
conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
Control group
normal controls obtained from border of excision biopsy of mucocele in the lip mucosa of healthy individuals.
CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction
new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction
conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction
new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction
conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CXPA of major and minor salivary glands (CXPA group).
* Border of excision biopsy of mucocele in the lip mucosa of healthy individuals used as normal controls (Control group).
* Surgical excision of tumors with no preoperative chemotherapy or radiotherapy. For parotid tumours partial or total parotidectomy, Surgery was performed with or without facial nerve preservation and the later was carried out commonly when the nerve was involved by tumour. For tumours in the other glands, complete surgical excision with the involved gland and the suspicious adjacent structures was performed.
Exclusion Criteria
* All mesenchymal origin salivary gland tumours.
* All inflammatory and cystic lesions of salivary glands.
* Metastasis in salivary glands.
* Patients received preoperative chemotherapy or radiotherapy.
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amina Fouad Farag
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amina Fouad Farag
Lecturer of Oral and Maxillofacial Pathology, Oral Pathology Department, Faculty of Dentistry
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amina F Farag, PhD
Role: PRINCIPAL_INVESTIGATOR
Faculty of Dentistry, October 6 University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Dentistry, October 6 University
Giza, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kesharwani P, Ma R, Sang L, Fatima M, Sheikh A, Abourehab MAS, Gupta N, Chen ZS, Zhou Y. Gold nanoparticles and gold nanorods in the landscape of cancer therapy. Mol Cancer. 2023 Jun 21;22(1):98. doi: 10.1186/s12943-023-01798-8.
Farag AF, Hassabou NF. CD24-gold nanocomposite as promising and sensitive biomarker for cancer stem cells in salivary gland tumors. Nanomedicine. 2022 Nov;46:102598. doi: 10.1016/j.nano.2022.102598. Epub 2022 Sep 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECO6U/5-2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.